rdale
-
RT @: "Who Says I Can't?" Jothy Rosenberg's incredible story. Wow.
4:03 AM Nov 22nd
from TweetDeck
-
RT @: RT @: Senate Bill Guts Intellectual Freedom in Comparative Effectiveness Research
2:49 AM Nov 20th
from TweetDeck
-
Panelist: Rx adherence is WAY MORE important for outcomes than current state of genomic targeted / pers med
12:26 PM Nov 19th
from TweetDeck
-
Noubar Afeyan, Flagship: Tech has nothing to do with adoption of new pers med tech: it is incentives, regs, reimbursement etc
8:41 AM Nov 19th
from TweetDeck
-
Blackbox proprietary (algorithm-based) Dx which can't be compared in 2nd lab should cause concern to Pt, MD, FDA
8:33 AM Nov 19th
from TweetDeck
-
Business conundrum! Pers Med is about smaller targeted therapies but is up against Pharma's reliance on blockbusters.
8:26 AM Nov 19th
from TweetDeck
-
Pers Med not all genes ... consider phenotype: eg BMI, HDL/LDL etc. "When all else fails, examine the patient!"
8:11 AM Nov 19th
from TweetDeck
-
Ayers: Good news on pers med: EML4-ALK related cancer therapy moved to Ph-3 very quickly
7:38 AM Nov 19th
from TweetDeck
-
Ayers: multiple molecular Dx on lung cancer limited by vol of tissue; need to multiplex; req's clear regulatory path
7:33 AM Nov 19th
from TweetDeck
-
Ayers: Gefitinib studies informed by genotypes enabled/informed continued dev (lessons from AZ Iressa)
7:30 AM Nov 19th
from TweetDeck
-
Ayers: co-dev of drug with companion diag makes clinical trial design more complex: 2-arms drug/placebo goes to 4 w/Dx arms
7:24 AM Nov 19th
from TweetDeck
-
Alison Ayers VP Oncology Pfizer: Pers Med Pharma perspective (onc focus): aiming for right Rx right Pt, improved survival
7:20 AM Nov 19th
from TweetDeck
-
Walcoff: is there a conflict between pop health management and pers med? Collins and Woodcock may disagree
6:37 AM Nov 19th
from TweetDeck
-
Sheila Walcoff, Partner, MWE (law firm) on Legislative perspective - Diag of Republican view:
6:34 AM Nov 19th
from TweetDeck
-
McKinsey Pers Med catalysts: approval process clarity, aligned incentives, appropriate coverage, long term view. Duh!
6:26 AM Nov 19th
from TweetDeck
-
McKinsey finds: Dx manufacturers like pers med Dx's - 2-4x higher margins (!) and 14% CAGR; dislike uncertainty on reimbursement
6:23 AM Nov 19th
from TweetDeck
-
McKinsey finds: Pharma perspectives on Pers Med: won't reduce drug dev costs; OTOH companion Dx might swing market share
6:21 AM Nov 19th
from TweetDeck
-
McKinsey finds Payors skeptical of pers med: no info on cost efficacy; Pt churn = pay now, another payor benefits later
6:18 AM Nov 19th
from TweetDeck
-
Jerel Davis, McKinsey study asks: are incentive challenges impeding the dev and adoption of personalized medicine?
6:12 AM Nov 19th
from TweetDeck
-
RT @: RT @: Printer ink is more expensive than vintage champagne, ounce for ounce. Most expensive liquid on planet.
5:52 AM Nov 19th
from TweetDeck
|
- Name Richard Dale
- Location Newton, MA
- Web http://venturecyc...
- Bio Venture Capitalist, Cyclist - hence "Venture Cyclist"
|
